Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities

v3.3.1.900
Accrued Liabilities and other Long-Term Liabilities
12 Months Ended
Dec. 31, 2015
Payables and Accruals [Abstract]  
Accrued Liabilities and other Long-Term Liabilities
9. Accrued Liabilities and other Long-Term Liabilities
 
In December 2012, the Company acquired certain manufacturing rights from Ovamed and agreed to pay an aggregate of $1.5 million, in three installments of $0.5 million on December 12, 2014, 2015 and 2016, respectively. As of December 31, 2015, the Company had not made any payments to Ovamed. On February 27, 2015, Ovamed, the Company’s supplier and manufacturer of TSO, filed for insolvency in Germany, a process similar to U.S. bankruptcy. The accrual is recorded on the Consolidated Balance Sheets as a current accrued expense of $1.5 million as of December 31, 2015, as a result of the bankruptcy notification. This obligation was recorded at its full value; accretion of the obligation was $166,000, $154,000 and $136,000 for the year ended December 31, 2015, 2014 and 2013, respectively, and is recorded as interest expense on the Consolidated Statements of Operations (see Note 8). On April 20, 2015, the Company decided to no longer pursue the development of TSO. As a result, the Company terminated all on-going TSO trials including its Phase 2A clinical trial in pediatric patients with autism spectrum disorder. A preliminary analysis of data from this trial failed to demonstrate any signal of activity.
 
The Company also had a collaboration agreement with Dr. Falk Pharma (“Falk”) in connection with the development of TSO. Under this agreement, Falk was to provide the Company with the Final Clinical Study Report (“CSR”). On August 3, 2015, Falk notified the Company that the CSR was complete and that access to the CSR was available. While the Company disputes the adequacy of the CSR and does not believe any payment is due to Falk, upon receipt of access to the CSR, the Company recorded a liability of €2.5 million ($2.8 million) in accrued expenses as of December 31, 2015.
 
Accrued expenses and other long-term liabilities consisted of the following ($ in thousands):
 
 
 
As of December 31,
 
 
 
2015
 
2014
 
Accrued expenses:
 
 
 
 
 
 
 
Professional fees
 
$
382
 
$
837
 
Salaries, bonuses and related benefits
 
 
2,492
 
 
598
 
Accrued severance
 
 
-
 
 
38
 
Ovamed manufacturing rights
 
 
1,500
 
 
1,000
 
Research and development
 
 
810
 
 
832
 
Dr. Falk Pharma milestone
 
 
2,717
 
 
 
 
Lease impairment
 
 
146
 
 
165
 
Other
 
 
523
 
 
213
 
Total accrued expenses
 
$
8,570
 
$
3,683
 
 
 
 
 
 
 
 
 
Other long-term liabilities:
 
 
 
 
 
 
 
Ovamed manufacturing rights – long-term component
 
 
-
 
 
334
 
Long-term lease abandonment charge
 
 
91
 
 
268
 
Deferred rent
 
 
493
 
 
120
 
Total other long-term liabilities
 
$
584
 
$
722